Abstract:The goal of this narrative review is to provide an overview of migraine pathophysiology, with an emphasis on the role of calcitonin gene‐related peptide (CGRP) within the context of the trigeminovascular system.Migraine is a prevalent and disabling neurological disease that is characterized in part by intense, throbbing, and unilateral headaches. Despite recent advances in understanding its pathophysiology, migraine still represents an unmet medical need, as it is often underrecognized and undertreated. Although CGRP has been known to play a pivotal role in migraine for the last 2 decades, this has now received more interest spurred by the early clinical successes of drugs that block CGRP signaling in the trigeminovascular system.This narrative review presents an update on the role of CGRP within the trigeminovascular system. PubMed searches were used to find recent (ie, 2016 to November 2018) published articles presenting new study results. Review articles are also included not as primary references but to bring these to the attention of the reader. Original research is referenced in describing the core of the narrative, and review articles are used to support ancillary points.The trigeminal ganglion neurons provide the connection between the periphery, stemming from the interface between the primary afferent fibers of the trigeminal ganglion and the meningeal vasculature and the central terminals in the trigeminal nucleus caudalis. The neuropeptide CGRP is abundant in trigeminal ganglion neurons, and is released from the peripheral nerve and central nerve terminals as well as being secreted within the trigeminal ganglion. Release of CGRP from the peripheral terminals initiates a cascade of events that include increased synthesis of nitric oxide and sensitization of the trigeminal nerves. Secreted CGRP in the trigeminal ganglion interacts with adjacent neurons and satellite glial cells to perpetuate peripheral sensitization, and can drive central sensitization of the second‐order neurons. A shift in central sensitization from activity‐dependent to activity‐independent central sensitization may indicate a mechanism driving the progression of episodic migraine to chronic migraine. The pathophysiology of cluster headache is much more obscure than that of migraine, but emerging evidence suggests that it may also involve hypersensitivity of the trigeminovascular system. Ongoing clinical studies with therapies targeted at CGRP will provide additional, valuable insights into the pathophysiology of this disorder.CGRP plays an essential role in the pathophysiology of migraine. Treatments that interfere with the functioning of CGRP in the peripheral trigeminal system are effective against migraine. Blocking sensitization of the trigeminal nerve by attenuating CGRP activity in the periphery may be sufficient to block a migraine attack. Additionally, the potential exists that this therapeutic strategy may also alleviate cluster headache as well.

Novel Calcitonin Gene-Related Peptide (CGRP) Interfering Migraine Therapies and Stroke—A Review

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond

Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine

Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine—Clinical Considerations

CGRP and the Trigeminal System in Migraine

CGRP Modulating Therapies: An Update

CGRP: vom Neuropeptid zum therapeutischen Target (Hintergründe und Pathophysiologie)

Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class

The Role of Calcitonin Gene Related Peptide (CGRP) in Neurogenic Vasodilation and Its Cardioprotective Effects

Potential benefits and possible risks of CGRP-targeted multitherapy in migraine

Inflammatory complications of CGRP monoclonal antibodies: a case series

Calcitonin gene-related peptide: a potential protective agent in cerebral ischemia-reperfusion injury

Developments in targeting calcitonin gene-related peptide

Bimodal functions of calcitonin gene-related peptide in the brain

The potential danger of blocking CGRP for treating migraine in CADASIL patients

Future targets for migraine treatment beyond CGRP

CGRP as the target of new migraine therapies — successful translation from bench to clinic

Calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine

Migraine Treatment: Towards New Pharmacological Targets

Calcitonin Gene-Related Peptide Prevents Blood–brain Barrier Injury and Brain Edema Induced by Focal Cerebral Ischemia Reperfusion

Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations